https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/biomarin-release-results-cln2-trial-being-carried-out-gosh/
Biomarin release results from CLN2 trial being carried out at GOSH
28 Jun 2016, 2:05 p.m.
Biomarin have released positive 48-week results from a clinical trial of cerliponase alfa treatment for CLN2 disease.
CLN2 disease is a form of Batten disease, a fatal neurodegenerative disease. It is the result of mutations in the TPP1/CLN2 gene causing deficient activity of the tripeptidyl peptidase 1 enzyme (TPP1). Cerliponase alfa treatment is a recombinant form of TPP1 and is designed to restore TPP1 enzyme activity.
In this Phase I/II trial, cerliponase alfa treatment was administered directly into the brain ventricles via intracerebroventricular infusions. At one year, the results have shown an 80 per cent reduction in the progression of the disease relating to decline in motor and language functioning, when compared to the natural progression of the disease. Furthermore, treatment was also found to reduce cortical grey matter loss.Biomarin plans to submit marketing applications and is planning to implement an early access programme to enable additional CLN2 patients to have access to this treatment.
The Great Ormond Street Hospital (GOSH) involvement in the trial was led by Novel Therapies Deputy Theme Lead, Professor Paul Gissen.
Working together to transform research
Our Highlight Report shines a spotlight on some of our brightest and best work in 2025-26. Our Impact report brings together a series of case studies and reflections that showcase the breadth and depth of PPIE across our organisation.
UK-wide excellence in paediatrics
Through the Paediatric Excellence Initiative, the NIHR GOSH Biomedical Research Centre is building a connected, collaborative UK-wide system to accelerate paediatric research.
Researchers identify brain network linked to deadliest childhood brain cancer
Researchers at GOSH and University College London have identified a human brain network associated with survival in children with diffuse midline glioma, the deadliest childhood brain cancer.
Families and researchers come together for BPAN Family Day
Families affected by BPAN came together with clinicians and researchers at GOSH